Table 1.

The correlation between clinicopathological variables and PLAAT4 expression in PAAD patients.

Characteristic	Low expression of PLAAT4	High expression of PLAAT4	p	method
n	89	89
T stage, n (%)			0.493	Fisher.test
T1	3 (1.7%)	4 (2.3%)
T2	15 (8.5%)	9 (5.1%)
T3	67 (38.1%)	75 (42.6%)
T4	2 (1.1%)	1 (0.6%)
N stage, n (%)			0.098	Chisq.test
N0	30 (17.3%)	20 (11.6%)
N1	55 (31.8%)	68 (39.3%)
M stage, n (%)			0.187	Fisher.test
M0	36 (42.9%)	43 (51.2%)
M1	4 (4.8%)	1 (1.2%)
Pathologic stage, n (%)			0.245	Fisher.test
Stage I	13 (7.4%)	8 (4.6%)
Stage II	67 (38.3%)	79 (45.1%)
Stage III	2 (1.1%)	1 (0.6%)
Stage IV	4 (2.3%)	1 (0.6%)
Primary therapy outcome, n (%)			0.167	Fisher.test
PD	20 (14.4%)	29 (20.9%)
SD	4 (2.9%)	5 (3.6%)
PR	3 (2.2%)	7 (5%)
CR	41 (29.5%)	30 (21.6%)
Radiation therapy, n (%)			1	Chisq.test
No	60 (36.8%)	58 (35.6%)
Yes	23 (14.1%)	22 (13.5%)
Residual tumor, n (%)			0.213	Fisher.test
R0	58 (35.4%)	49 (29.9%)
R1	21 (12.8%)	31 (18.9%)
R2	2 (1.2%)	3 (1.8%)
Age, n (%)			1	Chisq.test
≤65	47 (26.4%)	46 (25.8%)
>65	42 (23.6%)	43 (24.2%)
Race, n (%)			0.057	Fisher.test
Asian	9 (5.2%)	2 (1.1%)
Black or African American	4 (2.3%)	2 (1.1%)
White	74 (42.5%)	83 (47.7%)
Gender, n (%)			0.88	Chisq.test
Female	41 (23%)	39 (21.9%)
Male	48 (27%)	50 (28.1%)
Histologic grade, n (%)			<0.001	Fisher.test
G1	23 (13.1%)	8 (4.5%)
G2	48 (27.3%)	47 (26.7%)
G3	15 (8.5%)	33 (18.8%)
G4	2 (1.1%)	0 (0%)
Anatomic neoplasm subdivision, n (%)			0.209	Chisq.test
Head of Pancreas	65 (36.5%)	73 (41%)
Other	24 (13.5%)	16 (9%)